<p>Dalmia Healthcare on Thursday said it has started clinical trials to evaluate the efficacy and safety of its polyherbal combination 'Astha-15' for treatment of COVID-19.</p>.<p>All regulatory guidelines will be followed to conduct the multi-centric, Phase III clinical trials, the Dalmia Group firm said in a statement.</p>.<p><strong><a href="https://www.deccanherald.com/national/coronavirus-in-india-live-updates-today-lockdown-50-maharashtra-karnataka-tamil-nadu-mumbai-bangalore-delhi-bengaluru-kolkata-chennai-covid-19-news-world-narendra-modi-843634.html" target="_blank">For latest updates and live news on coronavirus, click here</a></strong></p>.<p>"We are conducting human trials of our highly efficient ayurvedic composition which can potentially help in curing COVID-19 patients," Dalmia Group of Companies Chairman Sanjay Dalmia said.</p>.<p>The polyherbal combination by the company has previously undergone a randomised double-blind, placebo-controlled study on patients in a speciality government hospital in Chennai, the statement said.</p>.<p>As per the study, the drug acts as a bronchodilator, decongestant, anti-inflammatory, lung detoxifier and did not show any side-effects, it added.</p>
<p>Dalmia Healthcare on Thursday said it has started clinical trials to evaluate the efficacy and safety of its polyherbal combination 'Astha-15' for treatment of COVID-19.</p>.<p>All regulatory guidelines will be followed to conduct the multi-centric, Phase III clinical trials, the Dalmia Group firm said in a statement.</p>.<p><strong><a href="https://www.deccanherald.com/national/coronavirus-in-india-live-updates-today-lockdown-50-maharashtra-karnataka-tamil-nadu-mumbai-bangalore-delhi-bengaluru-kolkata-chennai-covid-19-news-world-narendra-modi-843634.html" target="_blank">For latest updates and live news on coronavirus, click here</a></strong></p>.<p>"We are conducting human trials of our highly efficient ayurvedic composition which can potentially help in curing COVID-19 patients," Dalmia Group of Companies Chairman Sanjay Dalmia said.</p>.<p>The polyherbal combination by the company has previously undergone a randomised double-blind, placebo-controlled study on patients in a speciality government hospital in Chennai, the statement said.</p>.<p>As per the study, the drug acts as a bronchodilator, decongestant, anti-inflammatory, lung detoxifier and did not show any side-effects, it added.</p>